PERRIGO Co plc — Form 8-K
Filed November 4, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 62/100
What the filing says
Perrigo announced an agreement to sell its Infant Formula business for total consideration of up to $175 million ($40M upfront cash at closing plus up to $135M contingent on net sales milestones through 2030). The company expects to recognize an impairment loss of $275–375 million in Q4 2026 when the business is measured as held for sale. Q3 2026 core net sales declined 1.7% YoY to $908M; adjusted core EPS fell 9% to $0.61. The company narrowed full-year 2026 guidance for core organic net sales to –3.8% to –2.7% (prior: –3.0% to +1.0%) and core adjusted EPS to $2.15–$2.35 (prior: $2.25–$2.55), citing measured retailer inventory positioning and continued European softness.
Why this rating
Divestiture is strategically positive (portfolio simplification, margin improvement), but $275–375M impairment charge is ~7–10% of market cap and EPS guidance cut reflects operational weakness. Meaningful near-term earnings headwind despite long-term strategic rationale.
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.